0

Close
 
Upcoming Allied Market Research
2023
Hormone Refractory Breast Cancer Market

Hormone Refractory Breast Cancer Market

by Treatment Modality (Hormone receptor-based therapy, Tumor markers therapy, Gene expression therapy, Gene mutation therapy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A01149
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Hormone Refractory Breast Cancer Market

Request Now !

Breast cancer is one of the most common type of malignant cancers, which is prevalent in women above 40 years. As per World Health Organization (WHO) estimates, breast cancer accounted for around 521,000 deaths globally in 2012. Generally, hormone therapies are used for treating breast cancer, which subsequently leads to resistance after continuous use of hormone therapy. This resistance towards hormone therapy is termed as hormone refractory breast cancer. Hence, there is an increasing need for the effective treatment in hormone refractory breast cancer market. The market holds immense future potential, as there is no standard therapy, approved for hormone refractory breast cancer. However, there are rising hopes to get approved therapies in near future as drugs such as trastuzumab and everolimus, alone or in combination, are under development for the effective treatment of hormone refractory breast cancers.

The key factors driving growth of this market include, increasing global incidences of breast cancers, uprising prevalence rates of hormone refractory breast cancers, ageing population, demands of advanced therapeutics and increasing R&D investment on breast cancer drugs. The factors restraining the market growth are the social stigma related with breast cancer examinations, and insufficient advanced chemotherapeutic treatments. Substantial number of new chemical entities (NCEs) in different phases of clinical trials would emerge as a potential opportunity in the global hormone refractory breast cancer market.

The global market for hormone refractory breast cancer market is segmented on the basis of treatment modality and geography. The type of treatment modalities considered in this report include: hormone receptor-based therapy, tumor markers therapy, and gene expression therapy. Geographically, the market is segmented into four regions namely North America, Europe, Asia Pacific, and LAMEA. North America and Europe would lead the market owing to large number of affected population along with a high percentage of geriatric population and a significant number of research and drug development activities. The key market players considered in the report include AstraZeneca plc, Bluefish Pharmaceuticals AB, AmpliMed Corporation, Bioenvision Limited, F. Hoffmann-La Roche Ltd., Neopharm Ltd., NeoCorp GmbH, and Boehringer Ingelheim GmbH.

KEY MARKET BENEFITS

  • The analysis, made in this report, helps in understanding the strategies adopted by various companies for gaining market share in hormone refractory breast cancer market
  • The report provides the quantitative analysis of the current market and estimations that assists in identifying the prevailing market opportunities to capitalize on
  • This report provides a comprehensive analysis of factors that drive and restrict the growth of the hormone refractory breast cancer market
  • Detailed study of the strategies of key leaders, partnerships, and acquisitions in the global hormone refractory breast cancer market would be informative for professionals in the corporate sector
  • Pin-point analysis of geographic segments helps to identify opportunities for growth within the hormone refractory breast cancer market
  • Identification of key investment pockets for hormone refractory breast cancer market provide strategic assistance to decision makers
  • An analysis for the market attractiveness has been included for therapeutics, devices, and geographic regions along with a detailed analysis of factors responsible for the rapid growth of the market segments

 Hormone Refractory Breast Cancer Market Report Highlights

Aspects Details
By Treatment Modality
  • Hormone receptor-based therapy
  • Tumor markers therapy
  • Gene expression therapy
  • Gene mutation therapy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Eli Lilly and Company, Teva Pharmaceutical Industries Ltd,, Bioenvision Limited, Bluefish Pharmaceuticals AB, NeoCorp GmbH, Neopharm Ltd., AmpliMed Corporation, Boehringer Ingelheim GmbH., AstraZeneca plc, F. Hoffmann-La Roche Ltd.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: HORMONE REFRACTORY BREAST CANCER MARKET, BY TREATMENT MODALITY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment Modality

    • 4.2. Hormone Receptor-based Therapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Tumor Markers Therapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Gene Expression Therapy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Gene Mutation Therapy

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: HORMONE REFRACTORY BREAST CANCER MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Treatment Modality

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Hormone Refractory Breast Cancer Market

        • 5.2.4.1. Market Size and Forecast, By Treatment Modality

      • 5.2.5. Canada Hormone Refractory Breast Cancer Market

        • 5.2.5.1. Market Size and Forecast, By Treatment Modality

      • 5.2.6. Mexico Hormone Refractory Breast Cancer Market

        • 5.2.6.1. Market Size and Forecast, By Treatment Modality

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Treatment Modality

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Hormone Refractory Breast Cancer Market

        • 5.3.4.1. Market Size and Forecast, By Treatment Modality

      • 5.3.5. Germany Hormone Refractory Breast Cancer Market

        • 5.3.5.1. Market Size and Forecast, By Treatment Modality

      • 5.3.6. Italy Hormone Refractory Breast Cancer Market

        • 5.3.6.1. Market Size and Forecast, By Treatment Modality

      • 5.3.7. Spain Hormone Refractory Breast Cancer Market

        • 5.3.7.1. Market Size and Forecast, By Treatment Modality

      • 5.3.8. UK Hormone Refractory Breast Cancer Market

        • 5.3.8.1. Market Size and Forecast, By Treatment Modality

      • 5.3.9. Russia Hormone Refractory Breast Cancer Market

        • 5.3.9.1. Market Size and Forecast, By Treatment Modality

      • 5.3.10. Rest Of Europe Hormone Refractory Breast Cancer Market

        • 5.3.10.1. Market Size and Forecast, By Treatment Modality

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Treatment Modality

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Hormone Refractory Breast Cancer Market

        • 5.4.4.1. Market Size and Forecast, By Treatment Modality

      • 5.4.5. Japan Hormone Refractory Breast Cancer Market

        • 5.4.5.1. Market Size and Forecast, By Treatment Modality

      • 5.4.6. India Hormone Refractory Breast Cancer Market

        • 5.4.6.1. Market Size and Forecast, By Treatment Modality

      • 5.4.7. South Korea Hormone Refractory Breast Cancer Market

        • 5.4.7.1. Market Size and Forecast, By Treatment Modality

      • 5.4.8. Australia Hormone Refractory Breast Cancer Market

        • 5.4.8.1. Market Size and Forecast, By Treatment Modality

      • 5.4.9. Thailand Hormone Refractory Breast Cancer Market

        • 5.4.9.1. Market Size and Forecast, By Treatment Modality

      • 5.4.10. Malaysia Hormone Refractory Breast Cancer Market

        • 5.4.10.1. Market Size and Forecast, By Treatment Modality

      • 5.4.11. Indonesia Hormone Refractory Breast Cancer Market

        • 5.4.11.1. Market Size and Forecast, By Treatment Modality

      • 5.4.12. Rest of Asia Pacific Hormone Refractory Breast Cancer Market

        • 5.4.12.1. Market Size and Forecast, By Treatment Modality

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Treatment Modality

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Hormone Refractory Breast Cancer Market

        • 5.5.4.1. Market Size and Forecast, By Treatment Modality

      • 5.5.5. South Africa Hormone Refractory Breast Cancer Market

        • 5.5.5.1. Market Size and Forecast, By Treatment Modality

      • 5.5.6. Saudi Arabia Hormone Refractory Breast Cancer Market

        • 5.5.6.1. Market Size and Forecast, By Treatment Modality

      • 5.5.7. UAE Hormone Refractory Breast Cancer Market

        • 5.5.7.1. Market Size and Forecast, By Treatment Modality

      • 5.5.8. Argentina Hormone Refractory Breast Cancer Market

        • 5.5.8.1. Market Size and Forecast, By Treatment Modality

      • 5.5.9. Rest of LAMEA Hormone Refractory Breast Cancer Market

        • 5.5.9.1. Market Size and Forecast, By Treatment Modality

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning,2022

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. AstraZeneca Plc

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Bluefish Pharmaceuticals AB

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. AmpliMed Corporation

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Bioenvision Limited

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. F. Hoffmann-La Roche Ltd.

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. Neopharm Ltd.

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. NeoCorp GmbH

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Boehringer Ingelheim GmbH.

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Eli Lilly And Company

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. Teva Pharmaceutical Industries Ltd,

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET FOR HORMONE RECEPTOR-BASED THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET FOR TUMOR MARKERS THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE EXPRESSION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE MUTATION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. NORTH AMERICA HORMONE REFRACTORY BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. NORTH AMERICA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 9. U.S. HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 10. CANADA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 11. MEXICO HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 12. EUROPE HORMONE REFRACTORY BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. EUROPE HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 14. FRANCE HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 15. GERMANY HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 16. ITALY HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 17. SPAIN HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 18. UK HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 19. RUSSIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 20. REST OF EUROPE HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 21. ASIA-PACIFIC HORMONE REFRACTORY BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. ASIA-PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 23. CHINA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 24. JAPAN HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 25. INDIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 26. SOUTH KOREA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 27. AUSTRALIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 28. THAILAND HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 29. MALAYSIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 30. INDONESIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 31. REST OF ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 32. LAMEA HORMONE REFRACTORY BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 33. LAMEA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 34. BRAZIL HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 35. SOUTH AFRICA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 36. SAUDI ARABIA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 37. UAE HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 38. ARGENTINA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 39. REST OF LAMEA HORMONE REFRACTORY BREAST CANCER, BY TREATMENT MODALITY, 2022-2032 ($MILLION)
  • TABLE 40. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 41. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 42. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 43. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 44. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 45. BLUEFISH PHARMACEUTICALS AB: KEY EXECUTIVES
  • TABLE 46. BLUEFISH PHARMACEUTICALS AB: COMPANY SNAPSHOT
  • TABLE 47. BLUEFISH PHARMACEUTICALS AB: OPERATING SEGMENTS
  • TABLE 48. BLUEFISH PHARMACEUTICALS AB: PRODUCT PORTFOLIO
  • TABLE 49. BLUEFISH PHARMACEUTICALS AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 50. AMPLIMED CORPORATION: KEY EXECUTIVES
  • TABLE 51. AMPLIMED CORPORATION: COMPANY SNAPSHOT
  • TABLE 52. AMPLIMED CORPORATION: OPERATING SEGMENTS
  • TABLE 53. AMPLIMED CORPORATION: PRODUCT PORTFOLIO
  • TABLE 54. AMPLIMED CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 55. BIOENVISION LIMITED: KEY EXECUTIVES
  • TABLE 56. BIOENVISION LIMITED: COMPANY SNAPSHOT
  • TABLE 57. BIOENVISION LIMITED: OPERATING SEGMENTS
  • TABLE 58. BIOENVISION LIMITED: PRODUCT PORTFOLIO
  • TABLE 59. BIOENVISION LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 60. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 61. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 62. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 63. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 64. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 65. NEOPHARM LTD.: KEY EXECUTIVES
  • TABLE 66. NEOPHARM LTD.: COMPANY SNAPSHOT
  • TABLE 67. NEOPHARM LTD.: OPERATING SEGMENTS
  • TABLE 68. NEOPHARM LTD.: PRODUCT PORTFOLIO
  • TABLE 69. NEOPHARM LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 70. NEOCORP GMBH: KEY EXECUTIVES
  • TABLE 71. NEOCORP GMBH: COMPANY SNAPSHOT
  • TABLE 72. NEOCORP GMBH: OPERATING SEGMENTS
  • TABLE 73. NEOCORP GMBH: PRODUCT PORTFOLIO
  • TABLE 74. NEOCORP GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. BOEHRINGER INGELHEIM GMBH.: KEY EXECUTIVES
  • TABLE 76. BOEHRINGER INGELHEIM GMBH.: COMPANY SNAPSHOT
  • TABLE 77. BOEHRINGER INGELHEIM GMBH.: OPERATING SEGMENTS
  • TABLE 78. BOEHRINGER INGELHEIM GMBH.: PRODUCT PORTFOLIO
  • TABLE 79. BOEHRINGER INGELHEIM GMBH.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 81. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 82. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 83. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 84. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. TEVA PHARMACEUTICAL INDUSTRIES LTD,: KEY EXECUTIVES
  • TABLE 86. TEVA PHARMACEUTICAL INDUSTRIES LTD,: COMPANY SNAPSHOT
  • TABLE 87. TEVA PHARMACEUTICAL INDUSTRIES LTD,: OPERATING SEGMENTS
  • TABLE 88. TEVA PHARMACEUTICAL INDUSTRIES LTD,: PRODUCT PORTFOLIO
  • TABLE 89. TEVA PHARMACEUTICAL INDUSTRIES LTD,: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 3. SEGMENTATION HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 11. HORMONE REFRACTORY BREAST CANCER MARKET SEGMENTATION, BY BY TREATMENT MODALITY
  • FIGURE 12. HORMONE REFRACTORY BREAST CANCER MARKET FOR HORMONE RECEPTOR-BASED THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. HORMONE REFRACTORY BREAST CANCER MARKET FOR TUMOR MARKERS THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE EXPRESSION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE MUTATION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 17. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 18. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 19. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 20. COMPETITIVE DASHBOARD
  • FIGURE 21. COMPETITIVE HEATMAP: HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 22. Top player positioning, 2022
  • FIGURE 23. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 24. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 25. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 26. BLUEFISH PHARMACEUTICALS AB: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. BLUEFISH PHARMACEUTICALS AB: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. BLUEFISH PHARMACEUTICALS AB: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. AMPLIMED CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. AMPLIMED CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. AMPLIMED CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. BIOENVISION LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. BIOENVISION LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. BIOENVISION LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. NEOPHARM LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. NEOPHARM LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. NEOPHARM LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. NEOCORP GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. NEOCORP GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. NEOCORP GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. BOEHRINGER INGELHEIM GMBH.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. BOEHRINGER INGELHEIM GMBH.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. BOEHRINGER INGELHEIM GMBH.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. ELI LILLY AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. TEVA PHARMACEUTICAL INDUSTRIES LTD,: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Hormone Refractory Breast Cancer Market

Start reading.
This Report and over 68,131+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers